Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This monocentric, prospective, observational study will evaluate the safety and efficacy of
apatinib in combination with albumin binds paclitaxel and carboplatin or cisplatinum as
first-line treatment for stage II-IV epithelial ovarian cancer followed by apatinib
maintenance therapy in routine clinical practice. Eligible patients will be followed for
approximately 20 months.